You have the
hands of
a surgeon
and the
*eyes of an artist.*


That's why your
VISCOELASTIC
is HEALON®.

Trust the HEALON® OVDs to support your craft and provide premium protection for patient eyes throughout the cataract surgery

Healon®
FAMILY of OVDs

FROM THE
MAKERS OF
TECNIS®
Family of IOLs

Johnson&Johnson VISION

# INTRICATE PROCEDURES, DELIBERATE INSTRUMENTS

Your choice of IOL defines outcomes for patients…
but what about your OVD?

When it comes to a procedure as delicate as cataract surgery, you know the fine details matter. That's why your patients trust you to select the right IOL to provide exceptional visual outcomes.

A decision you may not weigh as heavily, though, is your choice of OVD. A silent but an essential tool to successful surgery that can be easy to overlook, OVDs' ability to **create and maintain space** while **protecting patients' eyes*** allows you to focus on your technique in every procedure.

*So, isn't it time you gave VISCOELASTICS a second look?*

With ***dispersive, cohesive, viscoadaptive,*** and ***dual-pack*** options, HEALON® OVDs offer the highest molecular weight** and provide the safety and precision that skilled surgeons demand.

* Refers to the protection of the corneal endothelium.

** Healon PRO and Healon GV PRO is compared with ProVisc (Alcon, Inc.) and Amvisc (B&L, Inc.). Healon5 PRO is compared with DisCoVisc (Alcon, Inc.) and Amvisc Plus (B&L, Inc.). Healon EndoCoat is compared with Viscoat (Alcon, Inc.) and Ocucoat (B&L, Inc.). Concentration may differ between all the compared OVDs. The compared OVDs have not been evaluated in a comparative clinical study.

Healon® FAMILY of OVDs

# *HEALON*® PRO

Clarity and reliability that supports your surgical technique

**Ideal for capsulorhexis and IOL insertion, *HEALON*® PRO cohesive OVD:**

- Provides excellent space creation and endothelial cell protection[1]
- Maintains a deep anterior chamber for efficient maneuvering and IOL implantation[1]
- Features easy injection and removal to support a smooth workflow[2,4,5]
- Is clear and transparent for facilitating visualization during procedures[1,2,5]




Overfilling the anterior or posterior segment of the eye with the Healon® PRO OVD may cause increased intraocular pressure, glaucoma, or other ocular damage. A transient rise of intraocular pressure postoperatively has been reported in some cases. Refer to the important safety information at the end.

Healon® FAMILY of OVDs

# *HEALON DUET*® PRO DUAL PACK

Protection and control, all in one convenient package

**A single convenient package to help streamline your case set-up, *HEALON Duet*® PRO gives you the benefits of both:**

- Premium protection via the HEALON EndoCoat® OVD[3]
- Reliable space creation with *HEALON*® PRO OVD[1]




Refer to the important safety information at the end.

Healon® FAMILY of OVDs

# HEALON ENDOCOAT®

Premium protection for patients' eyes
so you can focus on your craft

**To preserve the eye's integrity during procedures, HEALON EndoCoat® dispersive OVD:**

- Maintains anterior chamber, protects the corneal endothelium and other ocular tissue during cataract surgery[3]
- Is clear and transparent to afford you a more functional view during procedures


Pre-existing glaucoma, the surgery itself, or retained viscoelastic can cause increased intraocular pressure after the procedure. Due to the adherent nature of a dispersive viscoelastic more time and care may be required to remove the viscoelastic completely from the eye.
Refer to the important safety information at the end.

Healon®
FAMILY of OVDs

# *HEALON GV®* PRO

Easy space creation and OVD removal helps you apply the finishing touch to procedures

**When maximum chamber maintenance is needed, *HEALON GV®* PRO cohesive OVD:**

- Facilitates capsulorhexis by helping maintain a deep anterior chamber[6,10]
- Supports safe and controlled manipulation inside the eye with reduced trauma to the corneal endothelium[6]
- Features easy injection and removal from the anterior chamber[6,10]
- Creates and sustains a clear field of vision during surgery[6,10]




Postoperative intraocular pressure (IOP) may be increased if the *Healon GV®* PRO OVD is left in the eye. Special care should be taken to ensure complete removal of the *Healon GV®* PRO OVD from the entire eye including behind the lens and the chamber angles. Due to the greater viscosity of the *Healon GV®* PRO OVD, this increase in postoperative IOP may be higher than that caused by leaving the same amount of other sodium hyaluronate viscoelastic products, with lower zero shear viscosity, in the anterior chamber. Clinical judgement concerning the use of this product should be considered in cases where thorough removal may not be possible.
Refer to the important safety information at the end.

Healon®
FAMILY of OVDs

# *HEALON5*® PRO

## Complete control with an OVD that puts the full palette at your fingertips

**When both dispersive and cohesive OVD properties are desired, *HEALON5*® PRO Viscoadaptive OVD:**

- Provides space creation and anterior chamber maintenance through its cohesive properties[5,7]
- Delivers outstanding protection of endothelial cells during the phacoemulsification process through its dispersive properties[5,8,11]
- Helps maintain control during capsulorhexis, phacoemulsification, and IOL placement[5,9]


Special care should be taken to ensure complete removal of the Healon5® PRO OVD from the entire eye including behind the lens and the chamber angles. Due to the greater viscosity of the Healon5® PRO OVD, this increase in postoperative IOP may be higher than that caused by leaving the same amount of other sodium hyaluronate viscoelastic products, with lower zero shear viscosity, in the anterior chamber. Clinical judgement concerning the use of this product should be considered in cases where thorough removal may not be possible.
Refer to the important safety information at the end.

Healon®
FAMILY of OVDs

# HEALON® OVDs... one complete solution

## Artfully balance science and skill with the protection, control, and ease of use that define the HEALON® Family of OVDs


| PRODUCT | CLASSIFICATION | FILL SIZE | MOLECULAR WEIGHT | VISCOSITY |
|---|---|---|---|---|
| *HEALON*® PRO OVD | Cohesive | 0.55 mL<br>0.85 mL | 3,200,000 Da | 150,000 mPas |
| *HEALON Duet*® PRO Dual Pack<br>*HEALON*® PRO OVD<br>HEALON EndoCoat® OVD | <br>Cohesive<br>Dispersive | <br>0.55 mL<br>0.85 mL | <br>3,200,000 Da<br>800,000 Da | <br>150,000 mPas<br>50,000 cps |
| HEALON EndoCoat® OVD | Dispersive | 0.85 mL | 800,000 Da | 50,000 cps |
| *HEALON GV*® PRO | Cohesive | 0.85 mL | 3,200,000 Da | 2,000,000 mPas |
| *HEALON5*® PRO OVD | Viscoadaptive | 0.60 mL | 3,200,000 Da | 4,000,000 mPas |

**Learn more about why HEALON® should be your VISCOELASTIC partner of choice - especially when using TECNIS® IOLs - Talk to our specialists**

Johnson & Johnson VISION

**REFERENCES**

**1.** HEALON® PRO Cohesive OVD [package insert]. Santa Ana, CA: Johnson & Johnson Surgical Vision, Inc. **2.** Hutz WW. Eckhardt B, Kohnen T. Comparison of viscoelastic substances used in phacoemulsification. J Cataract Refract Surg. 1996:22:955-959 **3.** HEALON EndoCoat® Dispersive OVD [package insert]. Santa Ana, CA: Johnson & Johnson Surgical Vision, Inc. **4.** Bissen-Miyajima H. In vitro behavior of ophthalmic viscosurgical devices during phacoemulsification. J Cataract Refract Surg. 2006:32;1026-1031. **5.** Data on File. Johnson & Johnson surgical Vision, Inc. **6.** HEALON® GV PRO Cohesive OVD [package insert]. Santa Ana, CA: Johnson & Johnson Surgical Vision, Inc. **7.** Holmen, Jorgen B. Scheimpflug photography study of ophthalmic viscosurgical devices during simulated cataract surgery. J Cataract Refract Surg 2003:29(3)568-574. **8.** Holzer MP, et al. Effect of Healon5 and 4 other viscoelastic substances on intraocular pressure and endothelium after cataract surgery. J Cataract Refract Surg 2001: 27(2):213-218. **9.** Tetz MR, et al. Clinical results of phacoemulsification with the use of HEALON5 or VISCOAT J Cataract Refract Surg 2001: 27(3):416-420. **10.** Data on File - Evaluation of the rheological properties of Healon GV PRO OVD. **11.** Data on File - Clinical investigation of the bacterially-derived Healon5 OVD.



For healthcare professionals only. Please read the Directions for Use and consult our specialists if you have any questions.

## INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR HEALON® FAMILY OF PRODUCTS

**Rx Only**

**INDICATIONS for HEALON EndoCoat® OVD:** HEALON EndoCoat® OVD is an ophthalmic viscoelastic containing 3% sodium hyaluronate indicated for use as a surgical aid in patients undergoing ophthalmic anterior segment procedures including: Cataract surgery with an intraocular lens, Cataract surgery without an intraocular lens, Secondary intraocular lens implantation. HEALON EndoCoat® OVD maintains a deep chamber during anterior segment surgery, aids in tissue manipulation during surgery, enhances visualization during the surgical procedure and protects the corneal endothelium and other ocular tissue. The viscoelasticity of the solution maintains the normal position of the vitreous face and prevents formation of a flat chamber during surgery. It may also be used to coat intraocular lenses and insertion instruments prior to intraocular lens implantation.

**INDICATIONS for HEALON® PRO OVD:** The HEALON® PRO OVD is indicated for use as a surgical aid in cataract extraction (intra- and extracapsular), IOL implantation, corneal transplant, glaucoma filtration and retinal attachment surgery. In surgical procedures in the anterior segment of the eye, instillation of the HEALON® PRO OVD serves to maintain a deep anterior chamber during surgery, allowing for efficient manipulation with less trauma to the corneal endothelium and other surrounding tissues. Furthermore, its viscoelasticity helps to push back the vitreous face and prevent formation of a postoperative flat chamber. In posterior segment surgery the HEALON® PRO OVD serves as a surgical aid to gently separate, maneuver and hold tissues. The HEALON® PRO OVD creates a clear field of vision thereby facilitating intra- and post-operative inspection of the retina and photocoagulation.

**INDICATIONS for HEALON GV® PRO OVD:** The HEALON GV® PRO OVD is intended for use in anterior segment ophthalmic surgical procedures of the human eye. The HEALON GV® PRO OVD is designed to create and maintain a deep anterior chamber which facilitates manipulation inside the eye with reduced trauma to the corneal endothelium and other ocular tissues. The HEALON GV® PRO OVD can also be used to efficiently separate and control ocular tissues. The HEALON GV® PRO OVD is not designed to have any pharmacological effect.

**INDICATIONS for HEALON5® PRO OVD:** The HEALON5® PRO Ophthalmic Viscoelastic Device (OVD) is intended for use in anterior segment ophthalmic surgical procedures of the human eye. The HEALON5® PRO OVD is designed to create and maintain a deep anterior chamber which facilitates manipulation inside the eye with reduced trauma to the corneal endothelium and other ocular tissues. The HEALON5® PRO OVD can also be used to efficiently separate and control ocular tissues. The HEALON5® PRO OVD is not designed to have any pharmacological effect.

**CONTRAINDICATIONS:** There are no known contraindications to the use of HEALON® Family of OVDs when used as recommended.

**WARNINGS:** The HEALON EndoCoat® OVD delivery system is not designed or intended to be attached to instruments other than the one provided with the product, as it may cause cannula detachment. When using HEALON EndoCoat® OVD for surgery, the eye should not be irrigated with any solution containing benzalkonium chloride, because the mixing of quaternary ammonium salts, such as benzalkonium chloride, with sodium hyaluronate results in the formation of a precipitate.

**PRECAUTIONS:** Precautions normally considered during ophthalmic surgical procedures should be taken. The OVD may appear cloudy or form precipitates when it is injected. Should it be observed, remove the cloudy or precipitated material by irrigation and /or aspiration. Postoperative intraocular pressure (IOP) may be increased if the HEALON® OVDs are left in the eye. The potential for early and short-term post-operative IOP spikes exists with HEALON® OVDs (refers to HEALON PRO, HEALON5® PRO, HEALON EndoCoat® and HEALON GV® PRO OVDs) , that require time and care to remove from the eye. Therefore, it is recommended that the HEALON® OVDs be removed from the eye completely by irrigating and aspirating with sterile irrigation solution to reduce the risk of early postoperative IOP spikes. Special care should be taken to ensure complete removal of the HEALON GV® PRO and HEALON5® PRO OVD from the entire eye including behind the lens and the chamber angles to avoid intraocular pressure peaks postoperatively. Due to the greater viscosity of the HEALON GV® PRO and HEALON5® PRO OVD, this increase in postoperative IOP may be higher than that caused by leaving the same amount of other sodium hyaluronate viscoelastic products, with lower zero shear viscosity, in the anterior chamber. Product and cannula are for single use only. Re-use may cause eye inflammation. Express a small amount of the HEALON® OVDs from the syringe prior to use and carefully examine it during use to avoid injecting minute rubber particles which may be released when the syringe diaphragm is punctured. Injection of the HEALON EndoCoat® OVD creates pressure in the syringe. To prevent expulsion of the cannula into the eye, ensure that the cannula is securely attached to the fitting on the syringe. Use of the cannula guard is recommended. Extrusion of a test droplet is recommended prior to entering the eye, and excessive force on the plunger should be avoided. Postoperative intraocular pressure may also be elevated as a result of preexisting glaucoma, compromised outflow and by operative procedures and sequelae thereto, including enzymatic zonulysis, absence of an iridectomy, trauma to filtration structures, and by blood and lenticular remnants in the anterior chamber. Do not overfill the eye chambers with the HEALON® OVDs, completely remove the HEALON® OVDs by irrigation and/or aspiration at the close of the surgery and carefully monitor intraocular pressure, particularly during the early postoperative period. Treat with appropriate intraocular pressure lowering therapy, if required. Overfilling the anterior or posterior segment of the eye with the HEALON® PRO OVD may cause increased intraocular pressure, glaucoma, or other ocular damage. Pre-existing glaucoma, other causes of compromised outflow, higher preoperative intraocular pressure and complications in surgical procedures may also lead to increased intraocular pressure; consequently, extra care should be taken in patients with these conditions as described in the HEALON® OVDs Directions for Use. HEALON® OVD is a highly purified fraction extracted from microbial fermentation which may contain minute amounts of protein. The physician should be aware of the potential allergic risks such as postoperative inflammation that can occur with injection of biological materials. HEALON EndoCoat® OVD does not require refrigeration. If refrigerated, HEALON EndoCoat® OVD should be allowed to attain room temperature prior to use. Use only if the HEALON® OVD solution is clear.

**ADVERSE REACTIONS:** In posterior segment surgery intraocular pressure rises have been reported in some patients, especially in aphakic diabetics, after injection of large amounts of the HEALON® PRO OVD. There have been reports of transient postoperative ocular inflammation (oral and/or topical steroid treatments were administered) and transient postoperative increases in intraocular pressure during clinical trials with viscoelastics. In addition to the above, the following adverse reactions have been reported following the use of sodium hyaluronate in intraocular surgery: inflammation, corneal edema, increased intraocular pressure, secondary glaucoma and corneal decompensation. Rarely, postoperative inflammatory reactions (iritis, hypopyon, endophthalmitis) following the use of sodium hyaluronate have been reported.

**ADVERSE EVENTS:** Increased intraocular pressure is likely to occur if the HEALON® OVDs are not removed as completely as possible. Clinical judgement concerning the use of this product should be considered in cases where thorough removal may not be possible. Precautions noted above should be taken to reduce the likelihood of occurrence of related postoperative complications such as optic neuropathy, pupillary atonia and dilation, and iris atrophy.

**SERIOUS ADVERSE EVENTS:** The most frequently reported serious adverse events that occurred during the clinical trial of the HEALON5® PRO were intraocular pressure (IOP ) spikes ⩾30 mmHg (18 eyes, 8 .5 % ) and surgical reintervention (AC Taps to treat the elevated IOP, 7 eyes, 3 .3 % ). In the HEALON EndoCoat® study, ninety-two percent of the adverse events were IOP >30 mmHg; incidence of IOP >30 mmHg occurred at a rate of 10.5%. One subject in the HEALON EndoCoat® OVD group developed cystoid macular edema (CME) requiring treatment. This event was not considered by the investigators to be related to the viscoelastic used.

**ATTENTION** Reference the Directions for Use for a complete listing of Important Indications and Safety Information.

Johnson & Johnson VISION